Agnosia Treatment Market Research Report- Forecast till 2030

Agnosia Treatment Market: By Diagnosis (CT, MRI) Causes (Alzheimer's Disease, Pick's Disease, Melas, Balint's Syndrome) Type (Auditory Agnosia, Gustatory Agnosia, Olfactory Agnosia, Tactile Agnosia, Visual Agnosia) Treatment - Forecast till 2030

ID: MRFR/Pharma/3610-HCR | | Region: Global | 80 Pages         

Agnosia Treatment Market Scenario:


The global market of agnosia treatment is expected to reach USD 34,976 Million by 2030 at 3.2% CAGR during the forecast period 2022-2030.Agnosia is a rare neurological condition in which an individual may face difficulty to recognize a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.


People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.


Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.


Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.


The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).


Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.


There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.


Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.Segmentation


The agnosia treatment market is segmented on the basis of diagnosis, causes, type, and treatment.


On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.


On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.


On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia


On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole


Regional Analysis


The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.


North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.


Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.


Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.


Key Players



  • B. Braun Melsungen (Germany)

  • Pfizer Inc. (U.S.)

  • Lupin ltd. (India)

  • Fujifilm Holdings (Japan)

  • GE Healthcare (U.S.)

  • Siemens Healthcare(U.S.)

  • Philips Healthcare (U.S.)

  • F. Hoffmann-La Roche AG (Switzerland)

  • Aurobindo Pharma Ltd (India)

  • Sandoz GmBH (Austria)

  • Stellar- Bio Labs (India)

  • Fresenius Kabi Ipsum SRL (Italy)

  • Zhuhai United Laboratories Co Ltd (China)

  • Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China)

  • IPCA Labs ltd. (India)


Research Methodology Global Agnosia Treatment Market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Agnosia treatment Suppliers

  • Agnosia treatment Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

agnosia treatment market is projected to grow at a 3.2% CAGR between 2022-2030.

North America is projected to dominate the agnosia treatment market.

Different types of agnosia include visual agnosia, tactile agnosia, olfactory agnosia, gustatory agnosia, auditory agnosia, among others.

Some common causes of agnosia include Balint’s syndrome, Pick’s disease, and Alzheimer’s.

Eminent players profiled in the agnosia treatment market include IPCA Labs ltd. (India), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), Zhuhai United Laboratories Co Ltd (China), Fresenius Kabi Ipsum SRL (Italy), Stellar- Bio Labs (India), Sandoz GmBH (Austria), Aurobindo Pharma Ltd (India), F. Hoffmann-La Roche AG (Switzerland) , Philips Healthcare (U.S.), GE Healthcare (U.S.), Fujifilm Holdings (Japan), Lupin ltd. (India), Pfizer Inc. (U.S.), and B. Braun Melsungen (Germany).